Read by QxMD icon Read

Surgery ovarian cancer

Cindy Alcarraz, Johana Muñiz, Luis Mas, Mivael Olivera, Zaida Morante, Manuel Alvarez, Raul Mantilla, Jhajaira Araujo, Joseph Pinto
To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years)...
January 2018: Revista Peruana de Medicina Experimental y Salud Pública
Víctor Lago, Blas Flor, Luis Matute, Pablo Padilla-Iserte, Alvaro García-Granero, Marco Bustamante, Santiago Domingo
OBJECTIVE: Diverting ileostomy (DI) has been proposed to reduce the incidence and consequences anastomotic leakage after bowel resection. In colorectal cancer treatment, ghost ileostomy (GI) has been proposed as an alternative to DI. Our objective was to report the results of GI associated with colorectal resection in the treatment of ovarian cancer. MATERIALS AND METHODS: This is an observational pilot study performed in a single institution. The main objective sought was to report the results of GI associated with colorectal resection in the treatment of ovarian cancer: 26 patients were included...
June 19, 2018: International Journal of Gynecological Cancer
Laura Delgado-Ortega, Almudena González-Domínguez, Josep María Borrás, Juan Oliva-Moreno, Eva González-Haba, Salomón Menjón, Pedro Pérez, David Vicente, Luis Cordero, Margarita Jiménez, Susana Simón, Álvaro Hidalgo-Vega, Carlota Moya-Alarcón
OBJECTIVE: To assess the economic burden of epithelial ovarian cancer (EOC) in incident patients and the burden by disease stage in Spain. METHODS: We developed a Markov model from a social perspective simulating the natural history of EOC and its four stages, with a 10-year time horizon, 3-week cycles, 3% discount rate, and 2016 euros. Healthcare resource utilization and costs were estimated by disease stage. Direct healthcare costs (DHC) included early screening, genetic counselling, medical visits, diagnostic tests, surgery, chemotherapy, hospitalizations, emergency services, and palliative care...
June 19, 2018: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
Alyssa M Wield, Christine S Walsh, B J Rimel, Ilana Cass, Beth Y Karlan, Andrew J Li
Data from colon, breast and prostate cancers suggest that aspirin users have reduced mortality. While the direct mechanism remains uncertain, aspirin can suppress the COX-dependent and independent pathways involved in tumor progression. We hypothesized that aspirin users with clear cell ovarian cancer would have improved survival outcomes. We performed a retrospective review of patients with clear cell ovarian cancer diagnosed between 1995 and 2010, and followed outcomes through 2016. Patients underwent primary cytoreductive surgery followed by platinum-based chemotherapy...
August 2018: Gynecologic Oncology Reports
Muna Alemi Yahya, Shilhav Meisel Sharon, Shay Hantisteanu, Mordechai Hallak, Ilan Bruchim
Treatment of patients with gynecologic malignancies diagnosed at advanced stages remains a therapeutic challenge. Survival rates of these patients remain significantly low, despite surgery and chemotherapy. Advances in understanding the role of the immune system in the pathogenesis of cancer have led to the rapid evolution of immunotherapeutic approaches. Immunotherapeutic strategies, including targeting specific immune checkpoints, as well as dendritic cell (DC) immunotherapy are being investigated in several malignancies, including gynecological cancers...
2018: Frontiers in Endocrinology
Kayo Inoue, Hiroshi Tsubamoto, Keiko Ishida-Nisigami, Yoshitaka Torii, Seiichi Hirota
Ovarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent SCTs (Sigismondi et al., 2012), there is no established chemotherapy regimen for platinum-resistant recurrent SCTs. The effectiveness of pazopanib in treating epithelial ovarian cancer has recently been reported (du Bois et al., 2014; Pignata et al., 2015). In the case described herein, pazopanib was used to treat the platinum-resistant recurrence of a high-grade Sertoli cell tumor, and the response was evaluated by 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET)-computed tomography (CT)...
May 2018: Gynecologic Oncology Reports
Christina N Cordeiro Mitchell, Tricia Murdock, Amanda N Fader, Rebecca L Stone
•Abnormal cell free DNA results may indicate occult maternal malignancy.•Cesarean-cytoreductive surgery is feasible even with significant disease burden.•Carboplatin/paclitaxel is first line for epithelial ovarian cancer in pregnancy.
May 2018: Gynecologic Oncology Reports
Lu Qin, Huming Huang, Mengjie Chen, Yuejuan Liang, He Wang
BACKGROUND: The treatment of newly diagnosed advanced epithelial ovarian cancer (EOC) was predicted by an ovarian cancer computed tomography (CT) evaluation model combined with serum CA125. METHODS: Clinical data for 194 patients with advanced EOC treated with neoadjuvant chemotherapy (NACT) combined with interval debulking surgery (IDS) or primary debulking surgery (PDS) were retrospectively analyzed, and the appropriate treatment was predicted by comparing the subgroup differences in intraoperative situations, postoperative situations and survival rates...
June 18, 2018: Journal of Ovarian Research
Isabella Cadena, Victoria P Werth, Pascale Levine, Annie Yang, Andrea Downey, John Curtin, Franco Muggia
Could hydroxychloroquine and quinacrine antimalarial therapy for dermatomyositis later attributed to a paraneoplasic manifestation of an ovarian cancer enhance its subsequent response to chemotherapy? Five months after being diagnosed with dermatomyositis, while somewhat improved with hydroxychloroquine, quinacrine and methotrexate, this 63-year-old woman presented with an advanced intra-abdominal epithelial ovarian cancer documented (but not resected) at laparotomy. Neoadjuvant carboplatin/paclitaxel resulted in remarkable improvement of symptoms, tumour markers and imaging findings leading to thorough cytoreductive surgery at completion of five cycles...
2018: Ecancermedicalscience
Allison A Gockley, Kevin M Elias
Ovarian cancer remains the leading cause of gynecologic cancer death among American women. Prevention is the only proven approach to reduce the incidence of the disease. Oral contraception, tubal ligation, and risk-reducing salpingo-oophorectomy (rrBSO) for high-risk groups are all established risk reduction strategies. This paradigm is changing as recent biologic studies suggest that many ovarian cancers, especially high-grade serous ovarian cancers, originate in the distal end of the fallopian tube rather than the ovarian surface epithelium...
June 11, 2018: Cancer Treatment Reviews
Ilana Graetz, Janeane N Anderson, Caitlin N McKillop, Edward J Stepanski, Andrew J Paladino, Todd D Tillmanns
OBJECTIVE: Nearly 1 in 5 patients hospitalized for ovarian cancer surgery are readmitted for complications that may have been prevented with monitoring. We conducted a randomized controlled feasibility trial to evaluate a postoperative web-based app intervention to provide real-time symptom monitoring among patients diagnosed or with suspected gynecological cancer who had open bilateral salpingo-oophorectomy surgery. METHODS: Participants were randomized into two groups: (1) App + Reminder: had access to the app, and use was encouraged with daily and/or weekly reminders; (2) app: had access to the app but received no reminders...
June 11, 2018: Gynecologic Oncology
Audrey Tieko Tsunoda, Reitan Ribeiro, Rosilene Jara Reis, Carlos Eduardo Mattos da Cunha Andrade, Renato Moretti Marques, Glauco Baiocchi, Fabio Fin, Paulo Henrique Zanvettor, Deraldo Falcao, Thales Paulo Batista, Bruno Roberto Braga Azevedo, Gustavo Guitmann, Suzana Arenhart Pessini, João Soares Nunes, Leonardo Martins Campbell, José Clemente Linhares, Felipe José Fernandez Coimbra
Surgical management in epithelial ovarian cancer (EOC) has a significant impact in overall survival (OS) and progression free survival (PFS). Brazilian Society of Surgical Oncology (BSSO) supported a taskforce with experts for consensus: experienced and specialized trained surgeons, in cancer centers, provide the best EOC surgery. Laparoscopic and/or radiological staging prognosticate the possibility of complete cytoreduction (CC0) and help to reduce unnecessary laparotomies. Surgical techniques were reviewed...
June 14, 2018: BJOG: An International Journal of Obstetrics and Gynaecology
Linda R Duska
Surgery plays a critical role in all aspects of the management of ovarian cancer: from comprehensive staging of disease apparently confined to one ovary; to complete removal of advanced disease at the time of presentation; to appropriate surgical management of disease recurrence. As such, the surgeon plays an essential role in the management of this disease throughout its course. Appropriate and aggressive surgical management has been demonstrated in countless publications to improve overall survival from this disease...
June 14, 2018: BJOG: An International Journal of Obstetrics and Gynaecology
Tingyan Shi, Rong Jiang, Jinjin Yu, Huijuan Yang, Dongsheng Tu, Zhiyuan Dai, Yang Shen, Yuqin Zhang, Xi Cheng, Huixun Jia, Ruiqin Tu, Huaying Wang, Jie Tang, Yuting Luan, Shumo Cai, Rongyu Zang
BACKGROUND: We assessed the efficacy of adding intraperitoneal (IP) chemotherapy to standard first-line intravenous (IV) chemotherapy in epithelial ovarian cancer (EOC) patients. METHODS: Patients with stage IIIC-IV EOC who underwent optimal debulking surgery were randomly assigned to four cycles of weekly IP chemotherapy with cisplatin (50 mg/m2 ) and etoposide (100 mg/m2 ) followed by six cycles of IV chemotherapy every 3 weeks (IP/IV arm), or were administered IV chemotherapy alone (IV arm)...
June 14, 2018: British Journal of Cancer
Meral Gunaldi, Nilgun Isiksacan, Hakan Kocoglu, Yildiz Okuturlar, Omur Gunaldi, Turkan Ozturk Topcu, Mehmet Karabulut
Objective: Survivin is one of the apoptosis inhibitor proteins, and it plays a key role in tumor angiogenesis and cancer progression. This study was conducted to investigate the serum level of survivin to determine its diagnostic value in cancer patients. Materials and Methods: Blood samples were taken from cancer patients (n = 67) prior to surgery or chemo/radiotherapy and age-matched healthy volunteers (n = 23). The serum levels of survivin were analyzed by enzyme-linked immunosorbent assays...
April 2018: Journal of Cancer Research and Therapeutics
Roberta Lazzari, Sara Ronchi, Sara Gandini, Alessia Surgo, Stefania Volpe, Gaia Piperno, Stefania Comi, Floriana Pansini, Cristiana Fodor, Roberto Orecchia, Federica Tomao, Gabriella Parma, Nicoletta Colombo, Barbara Alicja Jereczek-Fossa
PURPOSE: To evaluate stereotactic body radiation therapy (SBRT) for metachronous oligometastatic ovarian cancer patients in terms of local control, delay of systemic treatment, survival outcomes, and toxicity. METHODS AND MATERIALS: Retrospective data collection from a single institution was performed. The inclusion criteria were as follows: (1) oligorecurrent or oligoprogressive disease in ovarian cancer patients during or after systemic therapy; (2) surgery or other local therapies not feasible; and (3) relative contraindication to systemic therapy for reasons such as unavailability of additional chemotherapy lines or refusal of the patient...
July 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Dimitrios Nasioudis, Evelyn Minis, Eloise Chapman-Davis, Melissa K Frey, Thomas A Caputo, Steven S Witkin, Kevin Holcomb
STUDY OBJECTIVE: Evaluate the prevalence, trends and outcomes of minimally invasive surgical staging (MIS) of malignant ovarian germ cell tumors (MOGCTs) apparently confined to the ovary. DESIGN: Retrospective cohort study (Canadian Task Force classification II-2) SETTING: Participating hospitals in the National Cancer Data Base PATIENTS: Women diagnosed between 2010-2014 with a MOGCT apparently confined to the ovary with information on the planned surgical approach...
June 8, 2018: Journal of Minimally Invasive Gynecology
Shitanshu Uppal, Ryan J Spencer, Laurel W Rice, Marcela G Del Carmen, R Kevin Reynolds, Jennifer J Griggs
OBJECTIVE: To evaluate the role of 30-day readmission rate as a quality of care metric in patients undergoing ovarian cancer surgery. METHODS: We performed a retrospective cohort study of women diagnosed between 2004 and 2013 with advanced-stage, high-grade, serous carcinoma who underwent primary treatment. Using the National Cancer Database, we compared the performance of hospital risk-adjusted 30-day readmission rate to other quality of care metrics (risk-adjusted 30- and 90-day mortality, rates of adherence to guideline-based care, and overall survival) within hospitals categorized by yearly case volume (10 or less, 11-20, 21-30, and 31 cases per year or more)...
June 6, 2018: Obstetrics and Gynecology
Lotte Linnemann Rønfeldt, Dorthe Hjort Jakobsen, Henrik Kehlet, Henriette Lipczak, Kasper Wennerwaldt
INTRODUCTION: Clinical practice guidelines (CPGs) support enhanced post-operative recovery and decrease morbidity. In addition, patient information leaflets (PILs) are associated with enhanced overall outcomes and improved patient satisfaction. The aim of this study was to provide an overview of the quality of CPGs and PILs in cancer surgery departments undertaking pulmonary lobectomy, nephrectomy, cystectomy, whipples, colorectal and ovarian surgery. METHODS: We conducted a cross-sectional descriptive study within 44 surgical departments in six cancer subspecialties: lung (n = 4), kidney (n = 9), bladder (n = 5), pancreas (n = 4), colorectal (n = 18) and ovarian (n = 4)...
June 2018: Danish Medical Journal
Engin Oral, Ovgu Aydin, Banu Aygun Kumbak, Sennur İlvan, Handan Yilmaz, Esra Tustas, Tugan Bese, Fuat Demirkiran, Macit Arvas
The aim of the study was to reveal the prevalence of concomitant endometriosis in malignant and borderline ovarian tumours. A retrospective analysis was performed of 530 patients with malignant ovarian tumours and 131 with borderline ovarian tumours, who underwent surgery in our hospital between 1995 and 2011. Forty-eight (7.3%) of 661 patients with malignant and borderline ovarian tumours were associated with endometriosis. Of the 48 endometriosis cases, 73% of those were atypical. Infertility was noted in 38% of patients with endometriosis-associated ovarian tumours...
June 8, 2018: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"